Josep Tabernero Selected Research

Oxaliplatin (Eloxatin)

8/2021	KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
10/2020	Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
1/2020	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.
1/2020	Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial.
12/2019	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
1/2019	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
1/2019	Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.
11/2018	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
10/2018	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
9/2018	The safety of ramucirumab for the treatment of colorectal cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Josep Tabernero Research Topics

Disease

214	Neoplasms (Cancer) 06/2022 - 06/2004
143	Colorectal Neoplasms (Colorectal Cancer) 04/2022 - 06/2004
36	Colonic Neoplasms (Colon Cancer) 02/2022 - 06/2004
30	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2007
23	Adenocarcinoma 01/2022 - 09/2006
19	Disease Progression 01/2020 - 06/2004
16	Stomach Neoplasms (Stomach Cancer) 03/2022 - 09/2006
16	Neutropenia 01/2020 - 06/2004
13	Carcinoma (Carcinomatosis) 01/2019 - 09/2006
12	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2011
11	Carcinogenesis 01/2019 - 06/2008
10	Breast Neoplasms (Breast Cancer) 05/2022 - 08/2007
9	Microsatellite Instability 04/2022 - 03/2011
8	COVID-19 01/2022 - 01/2020
7	Fatigue 10/2019 - 01/2013
6	Melanoma (Melanoma, Malignant) 01/2022 - 03/2011
6	Exanthema (Rash) 01/2019 - 01/2011
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 02/2012
6	Hypertension (High Blood Pressure) 05/2015 - 01/2011
5	Nausea 01/2019 - 01/2015
5	Diarrhea 01/2019 - 01/2007
5	Vomiting 01/2019 - 01/2007
5	Rectal Neoplasms (Rectal Cancer) 01/2017 - 12/2008
5	Febrile Neutropenia 05/2015 - 06/2004
5	Stomatitis 03/2015 - 04/2008
4	Thyroid Neoplasms (Thyroid Cancer) 01/2020 - 12/2009
4	Anemia 01/2020 - 03/2015
4	Asthenia 01/2019 - 01/2008
4	Peripheral Nervous System Diseases (PNS Diseases) 01/2019 - 05/2013
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018 - 06/2015
4	Hyperglycemia 09/2017 - 04/2008
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2017 - 03/2006
4	Lung Neoplasms (Lung Cancer) 06/2014 - 08/2010
4	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2013 - 06/2007
3	Adenocarcinoma of Lung 01/2022 - 12/2013
3	Cholangiocarcinoma 01/2022 - 08/2015
3	Leukopenia 01/2020 - 05/2015
3	Inflammation (Inflammations) 01/2019 - 01/2015

Drug/Important Bio-Agent (IBA)

52	Biomarkers (Surrogate Marker)IBA 05/2022 - 09/2006
44	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2021 - 06/2004
42	Cetuximab (Erbitux)FDA Link 04/2022 - 08/2005
38	ErbB Receptors (EGF Receptor)IBA 01/2022 - 08/2005
34	Pharmaceutical PreparationsIBA 01/2022 - 07/2009
33	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 06/2004
27	Leucovorin (Folinic Acid)FDA Link 01/2022 - 06/2004
25	Monoclonal AntibodiesIBA 01/2019 - 08/2005
24	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 01/2008
20	Biological ProductsIBA 04/2022 - 09/2006
19	Bevacizumab (Avastin)FDA Link 04/2022 - 08/2010
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2008
18	Panitumumab (Vectibix)FDA Link 01/2020 - 12/2008
13	Gemcitabine FDA Link 01/2020 - 10/2013
12	Tyrosine Kinase InhibitorsIBA 01/2022 - 08/2005
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 03/2007
12	RamucirumabIBA 10/2021 - 01/2014
10	AntibodiesIBA 04/2022 - 08/2010
10	afliberceptIBA 01/2022 - 10/2012
10	Capecitabine (Xeloda)FDA Link 08/2021 - 06/2004
9	Immune Checkpoint InhibitorsIBA 06/2022 - 05/2016
9	pembrolizumabIBA 01/2022 - 03/2017
9	trifluridine tipiracil drug combinationIBA 06/2021 - 05/2015
9	130-nm albumin-bound paclitaxelIBA 01/2020 - 10/2013
8	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 12/2015
7	encorafenibIBA 04/2022 - 01/2017
7	Trastuzumab (Herceptin)FDA Link 01/2021 - 08/2010
6	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 12/2011
6	regorafenibIBA 11/2021 - 01/2013
6	Cisplatin (Platino)FDA LinkGeneric 08/2021 - 11/2008
6	LigandsIBA 08/2021 - 12/2014
6	Everolimus FDA Link 04/2021 - 04/2008
6	XELOXIBA 11/2015 - 06/2004
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2021 - 12/2013
5	Dihydrotachysterol (AT 10)IBA 12/2018 - 01/2004
5	Cell-Free Nucleic AcidsIBA 01/2018 - 12/2011
5	Mechanistic Target of Rapamycin Complex 1IBA 01/2017 - 05/2011
5	Phosphotransferases (Kinase)IBA 07/2015 - 07/2009
4	AlbuminsIBA 01/2021 - 03/2012
4	binimetinibIBA 01/2021 - 10/2019
4	futuximabIBA 01/2020 - 06/2015
4	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 07/2015
4	MTOR InhibitorsIBA 12/2017 - 08/2010
4	CateninsIBA 02/2016 - 09/2011
4	Phosphatidylinositols (Phosphatidylinositol)IBA 06/2015 - 07/2013
3	Messenger RNA (mRNA)IBA 01/2022 - 04/2013
3	ipatasertibIBA 12/2021 - 12/2013
3	PlatinumIBA 08/2021 - 08/2008
3	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2015
3	dabrafenibIBA 01/2020 - 03/2011
3	trametinibIBA 01/2020 - 02/2015
3	LY-2157299IBA 11/2019 - 11/2018
3	Circulating Tumor DNAIBA 01/2019 - 01/2018
3	erdafitinibIBA 01/2019 - 07/2015

Therapy/Procedure

121	Therapeutics 03/2022 - 06/2004
58	Drug Therapy (Chemotherapy) 06/2022 - 06/2007
15	Adjuvant Chemotherapy 02/2022 - 06/2006
13	Immunotherapy 12/2021 - 01/2016
11	Precision Medicine 01/2022 - 07/2013
8	Radiotherapy 01/2020 - 12/2008
5	Chemoradiotherapy 01/2018 - 12/2008
5	Operative Surgical Procedures 01/2018 - 07/2007